We are live on ! Find out more
TRIL

Trillium Therapeutics Inc.
TRIL

Delisted

TRIL was delisted on the 16th of November, 2021.

Back to rankings

Fund managers haven’t disclosed any holdings of TRIL yet.

TRIL Hedge Fund Activity: Q1 2022 in Review

0 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q1 2022, worth a combined $0 — down 100% from $18K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of TRIL and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Optiver Holding, exiting entirely with an estimated $18K sold.

  • 0 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q1 2022, down from 2 in Q4 2021.
  • Funds reported $0 of Trillium Therapeutics Inc. stock for Q1 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Trillium Therapeutics Inc. positions in Q1 2022 and 2 closed out, a net change of -2 holders.
  • The largest Trillium Therapeutics Inc. seller in Q1 2022 was Optiver Holding, an estimated $18K sold.

Based on aggregated 13F filings for Q1 2022.